Genetic control of human androgen metabolism by the CYP17 and SRD5A2 genes

被引：0
|
作者：
Makridakis, N
Reichardt, J
Pike, M
Stanczyk, F
Yu, MM
Kolonel, L
Ross, R
Coetzee, G
Henderson, B
机构：
[1] USC, Sch Med, Los Angeles, CA USA
[2] Canc Res Ctr, Honolulu, HI USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 1997年 / 61卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
1497
引用
收藏
页码：A257 / A257
页数：1
相关论文
共 50 条
  • [1] Association of prostate cancer risk and aggressiveness to androgen pathway genes:: SRD5A2, CYP17, and the AR
    Cicek, MS
    Conti, DV
    Curran, A
    Neville, PJ
    Paris, PL
    Casey, G
    Witte, JS
    [J]. PROSTATE, 2004, 59 (01): : 69 - 76
  • [2] The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men
    Allen, NE
    Forrest, MS
    Key, TJ
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (03) : 185 - 189
  • [3] Genetic impact on prostate anatomical variability during ageing:: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms
    Larre, Stephane
    Hamadeh, Hikmat
    Azzouzi, Abdel Rahmene
    Vallancien, Guy
    Cochand-Priollet, Beatrix
    Cancel-Tassin, Geraldine
    Cussenot, Olivier
    [J]. BJU INTERNATIONAL, 2007, 100 (03) : 679 - 684
  • [4] Hypospadias Risk and Polymorphism in SRD5A2 and CYP17 Genes: Case-Control Study Among Indian Children
    Samtani, Ratika
    Bajpai, Minu
    Vashisht, Kapil
    Ghosh, P. K.
    Saraswathy, K. N.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (06): : 2334 - 2339
  • [5] Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
    Lunn, RM
    Bell, DA
    Mohler, JL
    Taylor, JA
    [J]. CARCINOGENESIS, 1999, 20 (09) : 1727 - 1731
  • [6] Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men
    El Ezzi, Asmahan Ali
    Zaidan, Wissam Rateeb
    El-Saidi, Mohammed Ahmed
    Al-Ahmadieh, Nabil
    Mortenson, Jeffrey Benjamin
    Kuddus, Ruhul Haque
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) : 1255 - 1262
  • [7] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2:: implication for prostate cancer risk
    Kakinuma, H
    Tsuchiya, N
    Habuchi, T
    Ohyama, C
    Matsuura, S
    Wang, L
    Nakamura, A
    Kato, T
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (04) : 333 - 337
  • [8] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk
    H Kakinuma
    N Tsuchiya
    T Habuchi
    C Ohyama
    S Matsuura
    L Wang
    A Nakamura
    T Kato
    [J]. Prostate Cancer and Prostatic Diseases, 2004, 7 : 333 - 337
  • [9] The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
    Onen, Ilke Hacer
    Ekmekci, Abdullah
    Eroglu, Muzaffer
    Polat, Fazli
    Biri, Hasan
    [J]. DNA AND CELL BIOLOGY, 2007, 26 (02) : 100 - 107
  • [10] Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population
    Yamada, Y
    Watanabe, M
    Murata, M
    Yamanaka, M
    Kubota, Y
    Ito, H
    Katoh, T
    Kawamura, J
    Yatani, R
    Shiraishi, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (05) : 683 - 686
12345